How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage).

Abstract:

:Indolent systemic mastocytosis (SM) patients have a varied clinical presentation, ranging from predominantly cutaneous symptoms to recurrent systemic symptoms (eg, flushing, palpitations, dyspepsia, diarrhea, bone pain) that can be severe and potentially life threatening (anaphylaxis). Mastocytosis patients without skin involvement pose a diagnostic challenge; a high index of suspicion is needed in those with mast cell-degranulation symptoms, including anaphylaxis following Hymenoptera stings or other triggers. Modern-era molecular and flow-cytometric diagnostic methods are very sensitive and can detect minimal involvement of bone marrow with atypical/clonal mast cells; in some cases, full diagnostic criteria for SM are not fulfilled. An important aspect of treatment is avoidance of known symptom triggers; other treatment principles include a stepwise escalation of antimediator therapies and consideration of cytoreductive therapies for those with treatment-refractory symptoms. The perioperative management of mastocytosis patients is nontrivial; a multidisciplinary preoperative assessment, adequate premedications, and close intra- and postoperative monitoring are critical. Smoldering mastocytosis is a variant with high systemic mast cell burden. While its clinical course can be variable, there is greater potential need for cytoreductive therapies (eg, interferon-alpha, cladribine) in this setting. A systematic approach to the diagnosis and treatment of indolent SM using a case-based approach of representative clinical scenarios is presented here.

journal_name

Blood

journal_title

Blood

authors

Pardanani A

doi

10.1182/blood-2013-01-453183

subject

Has Abstract

pub_date

2013-04-18 00:00:00

pages

3085-94

issue

16

eissn

0006-4971

issn

1528-0020

pii

blood-2013-01-453183

journal_volume

121

pub_type

杂志文章

相关文献

BLOOD文献大全
  • Increased death receptor resistance and FLIPshort expression in polycythemia vera erythroid precursor cells.

    abstract::Polycythemia vera (PV) is a clonal myeloproliferative disorder characterized by excessive erythrocyte production. Most patients with PV harbor an activating JAK2 mutation, but the molecular links between this mutation and erythrocyte overproduction are unknown. The interaction between death receptors and their ligands...

    journal_title:Blood

    pub_type: 杂志文章

    doi:10.1182/blood-2005-07-3037

    authors: Zeuner A,Pedini F,Signore M,Ruscio G,Messina C,Tafuri A,Girelli G,Peschle C,De Maria R

    更新日期:2006-05-01 00:00:00

  • Evidence for a role of glycoprotein IIb-IIIa, distinct from its ability to support aggregation, in platelet activation by ionophores in the presence of extracellular divalent cations.

    abstract::Ionophore A23187-induced 14C-serotonin secretion and thromboxane B2(TxB2) formation were found to be absent in citrated platelet-rich plasma (PRP) from thrombasthenic subjects and in normal PRP treated with glycoprotein (GP) IIb-IIIa complex-specific monoclonal antibodies. Both responses were restored to normal levels...

    journal_title:Blood

    pub_type: 杂志文章

    doi:

    authors: Lages B,Weiss HJ

    更新日期:1994-05-01 00:00:00

  • Inherited genetic susceptibility to monoclonal gammopathy of unknown significance.

    abstract::Monoclonal gammopathy of undetermined significance (MGUS) is present in ∼2% of individuals age >50 years. The increased risk of multiple myeloma (MM) in relatives of individuals with MGUS is consistent with MGUS being a marker of inherited genetic susceptibility to MM. Common single-nucleotide polymorphisms (SNPs) at ...

    journal_title:Blood

    pub_type: 杂志文章

    doi:10.1182/blood-2013-10-532283

    authors: Weinhold N,Johnson DC,Rawstron AC,Försti A,Doughty C,Vijayakrishnan J,Broderick P,Dahir NB,Begum DB,Hosking FJ,Yong K,Walker BA,Hoffmann P,Mühleisen TW,Langer C,Dörner E,Jöckel KH,Eisele L,Nöthen MM,Hose D,Davies

    更新日期:2014-04-17 00:00:00

  • Lentiviral gene transfer into peripheral blood-derived CD34+ NOD/SCID-repopulating cells.

    abstract::This study reports a lentiviral gene transfer protocol for efficient transduction of adult human peripheral blood (PB)-derived CD34+ NOD/SCID-repopulating cells (SRCs) using vesicular stomatitis virus-G protein (VSV-G)-pseudotyped lentiviruses encoding for enhanced green fluorescence protein (eGFP). Lentiviral stocks ...

    journal_title:Blood

    pub_type: 杂志文章

    doi:10.1182/blood.v99.2.709

    authors: Scherr M,Battmer K,Blömer U,Schiedlmeier B,Ganser A,Grez M,Eder M

    更新日期:2002-01-15 00:00:00

  • The morphological and biochemical characterization of a line of rat promegakaryoblasts.

    abstract::Biochemical and morphological evidence is presented to support the characterization of a rat bone-marrow-derived cell line (RPM) as an analog of the promegakaryoblast. The conditions for in vitro growth and maturation of the RPM line are described. Rapid proliferation of the RPM line is readily achieved when cultures ...

    journal_title:Blood

    pub_type: 杂志文章

    doi:

    authors: Weinstein R,Stemerman MB,MacIntyre DE,Steinberg HN,Maciag T

    更新日期:1981-07-01 00:00:00

  • KRASG12D expression in lung-resident myeloid cells promotes pulmonary LCH-like neoplasm sensitive to statin treatment.

    abstract::Langerhans cell histiocytosis (LCH) is a rare histiocytic neoplasm associated with somatic mutations in the genes involved in the RAF/MEK/extracellular signal-regulated kinase (ERK) signaling pathway. Recently, oncogenic mutations in NRAS/KRAS, upstream regulators of the RAF/MEK/ERK pathway, have been reported in pulm...

    journal_title:Blood

    pub_type: 杂志文章

    doi:10.1182/blood-2017-02-770149

    authors: Kamata T,Giblett S,Pritchard C

    更新日期:2017-07-27 00:00:00

  • Bryostatin 1 induces differentiation of B-chronic lymphocytic leukemia cells.

    abstract::Peripheral blood cells from nine patients with B-chronic lymphocytic leukemia (B-CLL) were treated in vitro with bryostatin 1 (a macrocyclic lactone derived from a marine invertebrate). Like the phorbol ester 12-0-tetradecanoyl-phorbol 13-acetate (TPA), bryostatin 1 activates protein kinase C (PKC), which plays a cent...

    journal_title:Blood

    pub_type: 杂志文章

    doi:

    authors: Drexler HG,Gignac SM,Jones RA,Scott CS,Pettit GR,Hoffbrand AV

    更新日期:1989-10-01 00:00:00

  • Human granulocyte colony-stimulating factor: biologic activities and receptor characterization on hematopoietic cells and small cell lung cancer cell lines.

    abstract::Human granulocyte colony-stimulating factor (G-CSF) is a regulatory glycoprotein that stimulates the production of neutrophilic granulocytes from committed hematopoietic progenitor cells both in vitro and in vivo. In this report, we show that biosynthetic (recombinant) human G-CSF enhances colony formation by normal h...

    journal_title:Blood

    pub_type: 杂志文章

    doi:

    authors: Avalos BR,Gasson JC,Hedvat C,Quan SG,Baldwin GC,Weisbart RH,Williams RE,Golde DW,DiPersio JF

    更新日期:1990-02-15 00:00:00

  • Regulation of early human hematopoietic (BFU-E and CFU-GEMM) progenitor cells in vitro by interleukin 1-induced fibroblast-conditioned medium.

    abstract::Stimulators of human erythroid burst-forming units (BFU-E) and multipotential colony-forming cells (CFU-GEMM) can be produced by a number of different cell types. A product of human peripheral blood monocytes, interleukin 1 (IL-1), was evaluated for its ability to stimulate fibroblast cultures to produce stimulators o...

    journal_title:Blood

    pub_type: 杂志文章

    doi:

    authors: Zucali JR,Broxmeyer HE,Dinarello CA,Gross MA,Weiner RS

    更新日期:1987-01-01 00:00:00

  • Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls.

    abstract::Ruxolitinib is JAK1/JAK2 inhibitor with established clinical benefit in myelofibrosis (MF). We analyzed long-term outcomes of 107 patients with intermediate-2 or high-risk MF receiving ruxolitinib at MD Anderson Cancer Center (MDACC) on phase 1/2 trial. After a median of 32 months of follow-up, 58 patients (54%) were ...

    journal_title:Blood

    pub_type: 杂志文章,多中心研究

    doi:10.1182/blood-2012-02-414631

    authors: Verstovsek S,Kantarjian HM,Estrov Z,Cortes JE,Thomas DA,Kadia T,Pierce S,Jabbour E,Borthakur G,Rumi E,Pungolino E,Morra E,Caramazza D,Cazzola M,Passamonti F

    更新日期:2012-08-09 00:00:00

  • Immunologic reconstitution after haploidentical bone marrow transplantation for immune deficiency disorders: treatment of bone marrow cells with monoclonal antibody CT-2 and complement.

    abstract::Patients with congenital T lymphocyte deficiency disorders received transplants with parental bone marrow depleted of mature T cells by the use of an anti-T cell monoclonal antibody (CT-2) and complement. Our results with 16 consecutive patients (20 transplants) showed rapid engraftment of donor cells; cytoreduction (...

    journal_title:Blood

    pub_type: 杂志文章

    doi:

    authors: Moen RC,Horowitz SD,Sondel PM,Borcherding WR,Trigg ME,Billing R,Hong R

    更新日期:1987-09-01 00:00:00

  • How I treat anticoagulated patients undergoing an elective procedure or surgery.

    abstract::The periprocedural management of patients receiving long-term oral anticoagulant therapy remains a common but difficult clinical problem, with a lack of high-quality evidence to inform best practices. It is a patient's thromboembolic risk that drives the need for an aggressive periprocedural strategy, including the us...

    journal_title:Blood

    pub_type: 杂志文章,评审

    doi:10.1182/blood-2012-06-415943

    authors: Spyropoulos AC,Douketis JD

    更新日期:2012-10-11 00:00:00

  • A genome-wide association analysis of serum iron concentrations.

    abstract::To investigate genetic variants that affect iron concentrations in persons not affected by overt genetic disorders of iron metabolism, a genome-wide association study was conducted in the InCHIANTI Study (N = 1206) and the Baltimore Longitudinal Study of Aging (N = 713). The top 2 single-nucleotide polymorphisms were ...

    journal_title:Blood

    pub_type: 杂志文章,meta分析

    doi:10.1182/blood-2009-07-232496

    authors: Tanaka T,Roy CN,Yao W,Matteini A,Semba RD,Arking D,Walston JD,Fried LP,Singleton A,Guralnik J,Abecasis GR,Bandinelli S,Longo DL,Ferrucci L

    更新日期:2010-01-07 00:00:00

  • The Mpl-ligand or thrombopoietin or megakaryocyte growth and differentiative factor has both direct proliferative and differentiative activities on human megakaryocyte progenitors.

    abstract::Previously, it was believed that megakaryocytopoiesis was regulated by two types of humoral factors: megakaryocyte colony-stimulating factor (MK-CSF), which acts on progenitors inducing their proliferation, and thrombopoietin (TPO), a megakaryocyte(s) (MK) maturational factor that induces platelet formation. The recen...

    journal_title:Blood

    pub_type: 杂志文章

    doi:

    authors: Debili N,Wendling F,Katz A,Guichard J,Breton-Gorius J,Hunt P,Vainchenker W

    更新日期:1995-10-01 00:00:00

  • A distinct pattern of cytokine gene expression by human CD83+ blood dendritic cells.

    abstract::Dendritic cells are the most potent antigen-presenting cells of the immune system. Although dendritic cells are likely to secrete selective cytokines that facilitate antigen presentation, the difficulty in isolating pure dendritic cells in sufficient numbers has made assessment of this function imprecise. In this stud...

    journal_title:Blood

    pub_type: 杂志文章

    doi:

    authors: Zhou LJ,Tedder TF

    更新日期:1995-11-01 00:00:00

  • A unique factor XIII inhibitor to a fibrin-binding site on factor XIIIA.

    abstract::An 81-year-old woman, who presented with sudden episodes of spontaneous bleeding, was found to have a specific inhibitor of factor XIII. Her fibrin clots had approximately 70% gamma-gamma and no alpha polymer formation, under conditions where normal fibrin was fully cross-linked; the patient's clots were soluble in ur...

    journal_title:Blood

    pub_type: 杂志文章

    doi:

    authors: Fukue H,Anderson K,McPhedran P,Clyne L,McDonagh J

    更新日期:1992-01-01 00:00:00

  • Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries.

    abstract::The myelodysplastic syndromes (MDSs) are hematologically diverse hematopoietic stem cell malignancies primarily affecting older individuals. The incidence of MDS in the United States is estimated at 3.3 per 100 000; however, evidence suggests underreporting of MDS to centralized cancer registries. Contrary to clinical...

    journal_title:Blood

    pub_type: 杂志文章

    doi:10.1182/blood-2011-02-337964

    authors: Cogle CR,Craig BM,Rollison DE,List AF

    更新日期:2011-06-30 00:00:00

  • Controlled trial of filgrastim for acceleration of neutrophil recovery after allogeneic blood stem cell transplantation from human leukocyte antigen-matched related donors.

    abstract::The rapid recovery of hematopoiesis after allogeneic blood stem cell transplantation has been attributed to the quality and quantity of hematopoietic progenitors in the blood stem cell grafts from filgrastim-stimulated donors. To determine whether further stimulation with filgrastim after transplantation would affect ...

    journal_title:Blood

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1182/blood.v97.11.3405

    authors: Przepiorka D,Smith TL,Folloder J,Anderlini P,Chan KW,Körbling M,Lichtiger B,Norfleet F,Champlin R

    更新日期:2001-06-01 00:00:00

  • Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model.

    abstract::Growing evidence indicates antibody-dependent cellular cytotoxicity (ADCC) contributes to the clinical response to monoclonal antibody (mAb) therapy of lymphoma. Recent in vitro analysis suggests C3b can inhibit mAb-induced natural killer (NK)-cell activation and ADCC. Further studies were conducted to assess the effe...

    journal_title:Blood

    pub_type: 杂志文章

    doi:10.1182/blood-2009-01-200469

    authors: Wang SY,Veeramani S,Racila E,Cagley J,Fritzinger DC,Vogel CW,St John W,Weiner GJ

    更新日期:2009-12-17 00:00:00

  • Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses.

    abstract::Fifty patients with Philadelphia chromosome-positive (Ph(+)) chronic myelogenous leukemia (CML) in early chronic phase received imatinib mesylate, 400 mg orally daily. After a median follow-up of 9 months, 49 patients (98%) achieved a complete hematologic response and 45 patients (90%) achieved a major cytogenetic res...

    journal_title:Blood

    pub_type: 临床试验,杂志文章

    doi:10.1182/blood-2002-02-0545

    authors: Kantarjian HM,Cortes JE,O'Brien S,Giles F,Garcia-Manero G,Faderl S,Thomas D,Jeha S,Rios MB,Letvak L,Bochinski K,Arlinghaus R,Talpaz M

    更新日期:2003-01-01 00:00:00

  • FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma.

    abstract::FTY720 is an immunosuppressant developed to prevent organ transplant rejection. Recent studies indicate an additional role for FTY720 in inducing cell apoptosis. We demonstrate here that FTY720 mediates toxic effects in cell lines representing different B-cell malignancies and primary B cells from patients with chroni...

    journal_title:Blood

    pub_type: 杂志文章

    doi:10.1182/blood-2006-10-053884

    authors: Liu Q,Zhao X,Frissora F,Ma Y,Santhanam R,Jarjoura D,Lehman A,Perrotti D,Chen CS,Dalton JT,Muthusamy N,Byrd JC

    更新日期:2008-01-01 00:00:00

  • CHAI and LATAIE: new genetic diseases of CTLA-4 checkpoint insufficiency.

    abstract::CTLA-4 is a critical inhibitory "checkpoint" molecule of immune activation. Several recent reports have described patients with immune dysregulation and lymphoproliferative disease resulting from 2 different genetic diseases that directly or indirectly cause CTLA-4 deficiency. Numerous articles have also been publishe...

    journal_title:Blood

    pub_type: 杂志文章,评审

    doi:10.1182/blood-2016-04-712612

    authors: Lo B,Fritz JM,Su HC,Uzel G,Jordan MB,Lenardo MJ

    更新日期:2016-08-25 00:00:00

  • Alloantibodies in von Willebrand disease.

    abstract::The development of alloantibodies against von Willebrand factor (VWF) represents a rare but serious complication of treatment of von Willebrand disease (VWD), occurring in ~5% to 10% of type 3 VWD patients. Affected patients can present with a range of symptoms, including lack or loss of hemostatic response to infused...

    journal_title:Blood

    pub_type: 杂志文章,评审

    doi:10.1182/blood-2012-10-462085

    authors: James PD,Lillicrap D,Mannucci PM

    更新日期:2013-08-01 00:00:00

  • IgE alone stimulates mast cell adhesion to fibronectin via pathways similar to those used by IgE + antigen but distinct from those used by Steel factor.

    abstract::We recently demonstrated that immunoglobulin E (IgE), in the absence of cross-linking agents, activates signaling pathways in healthy murine bone marrow-derived mast cells (BMMCs) and that this activation enhances BMMC survival, at least in part, via secretion of autocrine-acting cytokines. We report herein that IgE a...

    journal_title:Blood

    pub_type: 杂志文章

    doi:10.1182/blood-2002-10-3176

    authors: Lam V,Kalesnikoff J,Lee CW,Hernandez-Hansen V,Wilson BS,Oliver JM,Krystal G

    更新日期:2003-08-15 00:00:00

  • Transcription of the activating receptor NKG2D in natural killer cells is regulated by STAT3 tyrosine phosphorylation.

    abstract::Signal transducer and activator of transcription 3 (STAT3) is considered a negative regulator of inflammation, as inhibition of STAT3 signaling enhances antitumor immunity. However, STAT3 activation is a key oncogenic pathway in natural killer (NK)-lineage large granular lymphomas, and we recently reported enhanced pr...

    journal_title:Blood

    pub_type: 杂志文章

    doi:10.1182/blood-2013-05-499707

    authors: Zhu S,Phatarpekar PV,Denman CJ,Senyukov VV,Somanchi SS,Nguyen-Jackson HT,Mace EM,Freeman AF,Watowich SS,Orange JS,Holland SM,Lee DA

    更新日期:2014-07-17 00:00:00

  • Amelioration of Sardinian beta0 thalassemia by genetic modifiers.

    abstract::Sardinian beta-thalassemia patients all are homozygotes for the same null allele in the beta-globin gene, but the clinical manifestations are extremely variable in severity. Previous studies have shown that the coinheritance of alpha-thalassemia or the presence of genetic variants that sustain fetal hemoglobin product...

    journal_title:Blood

    pub_type: 杂志文章

    doi:10.1182/blood-2009-04-217901

    authors: Galanello R,Sanna S,Perseu L,Sollaino MC,Satta S,Lai ME,Barella S,Uda M,Usala G,Abecasis GR,Cao A

    更新日期:2009-10-29 00:00:00

  • EBV-tissue positive primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity.

    abstract::Primary central nervous system lymphoma (PCNSL) is confined to the brain, eyes, and cerebrospinal fluid without evidence of systemic spread. Rarely, PCNSL occurs in the context of immunosuppression, e.g. post-transplant lymphoproliferative disorders (PTLD) or HIV (AIDS-related PCNSL). These cases are poorly characteri...

    journal_title:Blood

    pub_type: 杂志文章

    doi:10.1182/blood.2020008520

    authors: Gandhi MK,Hoang T,Law SC,Brosda S,O'Rourke K,Tobin JWD,Vari F,Murigneux V,Fink JL,Gunawardana J,Gould CM,Oey H,Bednarska K,Delecluse S,Trappe RU,de Long LM,Sabdia MB,Bhagat G,Hapgood G,Blyth E,Clancy LE,Wight J

    更新日期:2020-11-17 00:00:00

  • Cell surface peptidase CD26/DPPIV mediates G-CSF mobilization of mouse progenitor cells.

    abstract::CXC ligand 12 (CXCL12; also known as stromal cell-derived factor 1alpha/SDF-1alpha) chemoattracts hematopoietic stem and progenitor cells (HSCs/HPCs) and is thought to play a crucial role in the mobilization of HSCs/HPCs from the bone marrow. CD26 (dipeptidylpeptidase IV [DPPIV]) is a membrane-bound extracellular pept...

    journal_title:Blood

    pub_type: 杂志文章

    doi:10.1182/blood-2002-12-3893

    authors: Christopherson KW 2nd,Cooper S,Broxmeyer HE

    更新日期:2003-06-15 00:00:00

  • Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns.

    abstract::Chronic lymphocytic leukemia is characterized by relapse after treatment and chemotherapy resistance. Similarly, in other malignancies leukemia cells accumulate mutations during growth, forming heterogeneous cell populations that are subject to Darwinian selection and may respond differentially to treatment. There is ...

    journal_title:Blood

    pub_type: 杂志文章

    doi:10.1182/blood-2012-05-433540

    authors: Schuh A,Becq J,Humphray S,Alexa A,Burns A,Clifford R,Feller SM,Grocock R,Henderson S,Khrebtukova I,Kingsbury Z,Luo S,McBride D,Murray L,Menju T,Timbs A,Ross M,Taylor J,Bentley D

    更新日期:2012-11-15 00:00:00

  • Fanconi anemia group J mutation abolishes its DNA repair function by uncoupling DNA translocation from helicase activity or disruption of protein-DNA complexes.

    abstract::Fanconi anemia (FA) is a genetic disease characterized by congenital abnormalities, bone marrow failure, and susceptibility to leukemia and other cancers. FANCJ, one of 13 genes linked to FA, encodes a DNA helicase proposed to operate in homologous recombination repair and replicational stress response. The pathogenic...

    journal_title:Blood

    pub_type: 杂志文章

    doi:10.1182/blood-2009-11-256016

    authors: Wu Y,Sommers JA,Suhasini AN,Leonard T,Deakyne JS,Mazin AV,Shin-Ya K,Kitao H,Brosh RM Jr

    更新日期:2010-11-11 00:00:00